Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 2
1970 1
1971 4
1973 2
1974 1
1978 1
1980 1
1981 1
1984 6
1985 3
1986 2
1987 3
1989 4
1990 4
1991 3
1992 2
1993 5
1994 5
1995 2
1996 5
1997 3
1998 2
1999 1
2000 6
2001 2
2002 1
2003 13
2004 7
2005 15
2006 15
2007 12
2008 16
2009 12
2010 19
2011 21
2012 27
2013 28
2014 13
2015 21
2016 29
2017 33
2018 30
2019 21
2020 47
2021 20
2022 25
2023 15
2024 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

501 results

Results by year

Filters applied: . Clear all
Page 1
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J, Ye X, Rousseau E, Januario T, Hamman BD, Rose CM, Cheung TK, Hinkle T, Soto L, Quinn C, Harbin A, Bortolon E, Chen X, Haskell R, Lin E, Yu SF, Del Rosario G, Chan E, Dunlap D, Koeppen H, Martin S, Merchant M, Grimmer M, Broccatelli F, Wang J, Pizzano J, Dragovich PS, Berlin M, Yauch RL. Cantley J, et al. Among authors: yu sf. Nat Commun. 2022 Nov 10;13(1):6814. doi: 10.1038/s41467-022-34562-5. Nat Commun. 2022. PMID: 36357397 Free PMC article.
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity.
Pillow TH, Adhikari P, Blake RA, Chen J, Del Rosario G, Deshmukh G, Figueroa I, Gascoigne KE, Kamath AV, Kaufman S, Kleinheinz T, Kozak KR, Latifi B, Leipold DD, Sing Li C, Li R, Mulvihill MM, O'Donohue A, Rowntree RK, Sadowsky JD, Wai J, Wang X, Wu C, Xu Z, Yao H, Yu SF, Zhang D, Zang R, Zhang H, Zhou H, Zhu X, Dragovich PS. Pillow TH, et al. Among authors: yu sf. ChemMedChem. 2020 Jan 7;15(1):17-25. doi: 10.1002/cmdc.201900497. Epub 2019 Nov 14. ChemMedChem. 2020. PMID: 31674143
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR. Shen BQ, et al. Among authors: yu sf. Nat Biotechnol. 2012 Jan 22;30(2):184-9. doi: 10.1038/nbt.2108. Nat Biotechnol. 2012. PMID: 22267010
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG. Dornan D, et al. Among authors: yu sf. Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub 2009 Jul 24. Blood. 2009. PMID: 19633198 Free article.
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Lewis GD, Li G, Guo J, Yu SF, Fields CT, Lee G, Zhang D, Dragovich PS, Pillow T, Wei B, Sadowsky J, Leipold D, Wilson T, Kamath A, Mamounas M, Lee MV, Saad O, Choeurng V, Ungewickell A, Monemi S, Crocker L, Kalinsky K, Modi S, Jung KH, Hamilton E, LoRusso P, Krop I, Schutten MM, Commerford R, Sliwkowski MX, Cho E. Lewis GD, et al. Among authors: yu sf. Nat Commun. 2024 Jan 11;15(1):466. doi: 10.1038/s41467-023-44533-z. Nat Commun. 2024. PMID: 38212321 Free PMC article. Clinical Trial.
cAMP Signalling Pathway in Biocontrol Fungi.
Sun ZB, Yu SF, Wang CL, Wang L. Sun ZB, et al. Among authors: yu sf. Curr Issues Mol Biol. 2022 Jun 4;44(6):2622-2634. doi: 10.3390/cimb44060179. Curr Issues Mol Biol. 2022. PMID: 35735620 Free PMC article. Review.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Lasater EA, Amin DN, Bannerji R, Mali RS, Barrett K, Rys RN, Oeh J, Lin E, Sterne-Weiler T, Ingalla ER, Go M, Yu SF, Krem MM, Arthur C, Hahn U, Johnston A, Karur V, Khan N, Marlton P, Phillips T, Gritti G, Seymour JF, Tani M, Yuen S, Martin S, Chang MT, Rose CM, Pham VC, Polson AG, Chang Y, Wever C, Johnson NA, Jiang Y, Hirata J, Sampath D, Musick L, Flowers CR, Wertz IE. Lasater EA, et al. Among authors: yu sf. Am J Hematol. 2023 Mar;98(3):449-463. doi: 10.1002/ajh.26809. Epub 2023 Jan 17. Am J Hematol. 2023. PMID: 36594167 Free article. Clinical Trial.
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity.
Herault A, Mak J, de la Cruz-Chuh J, Dillon MA, Ellerman D, Go M, Cosino E, Clark R, Carson E, Yeung S, Pichery M, Gador M, Chiang EY, Wu J, Liang Y, Modrusan Z, Gampa G, Sudhamsu J, Kemball CC, Cheung V, Nguyen TTT, Seshasayee D, Piskol R, Totpal K, Yu SF, Lee G, Kozak KR, Spiess C, Walsh KB. Herault A, et al. Among authors: yu sf. Cancer Immunol Immunother. 2024 Aug 8;73(10):209. doi: 10.1007/s00262-024-03795-2. Cancer Immunol Immunother. 2024. PMID: 39112670 Free PMC article.
501 results